Astellas Pharma (ALPMF) Stock Forecast & Price Target

Compare

51 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ALPMF Analyst Ratings

Moderate Buy

2 Buy

1 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Astellas

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ALPMF Stock 12 Month Forecast

Average Price Target

$11.96

▲(19.60%Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Astellas Pharma in the last 3 months. The average price target is $11.96 with a high forecast of $14.90 and a low forecast of $10.16. The average price target represents a 19.60% change from the last price of $10.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","15":"$15","9.75":"$9.75","11.5":"$11.5","13.25":"$13.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.16</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,9.75,11.5,13.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.64,10.044615384615385,10.44923076923077,10.853846153846154,11.258461538461539,11.663076923076924,12.067692307692308,12.472307692307693,12.876923076923077,13.281538461538462,13.686153846153847,14.090769230769231,14.495384615384616,{"y":14.9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.64,9.81846153846154,9.996923076923078,10.175384615384615,10.353846153846154,10.532307692307693,10.710769230769232,10.88923076923077,11.067692307692308,11.246153846153847,11.424615384615386,11.603076923076923,11.781538461538462,{"y":11.96,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.64,9.68,9.72,9.76,9.8,9.84,9.88,9.92,9.96,10,10.040000000000001,10.08,10.120000000000001,{"y":10.16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.54,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.34,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.88,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.6,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.62,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.37,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.51,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.95,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$14.90

Average Price Target$11.96

Lowest Price Target$10.16

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Shinichiro MuraokaMorgan Stanley

Morgan Stanley

$10.16

Hold

1.58%

Upside

Reiterated

05/30/25

Morgan Stanley Sticks to Its Hold Rating for Astellas Pharma (ALPMF)

Miki SogiBernstein

Bernstein

$12.87→$10.84

Buy

8.35%

Upside

Reiterated

05/08/25

Analysts Offer Insights on Healthcare Companies: aTyr Pharma (NASDAQ: ATYR), Vir Biotechnology (NASDAQ: VIR) and Astellas Pharma (Other OTC: ALPMF)

Hidemaru YamaguchiCiti

Citi

$16.25→$14.9

Buy

48.98%

Upside

Reiterated

05/01/25

Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,200 at CitiCiti analyst Hidemaru Yamaguchi lowered the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,200.00 (from JPY2,400.00) while maintaining a Buy rating.

Stephen BarkerJefferies

Jefferies

$10.16

Hold

1.58%

Upside

Reiterated

04/24/25

Analysts Offer Insights on Healthcare Companies: Astellas Pharma (Other OTC: ALPMF), Penumbra (NYSE: PEN) and Genmab (NASDAQ: GMAB)

Seiji WakaoJ.P. Morgan

J.P. Morgan

$11.65→$11.51

Hold

15.12%

Upside

Reiterated

03/05/25

J.P. Morgan Remains a Hold on Astellas Pharma (ALPMF)

Tony RenMacquarie

Macquarie

$14.9→$13.54

Buy

35.44%

Upside

Reiterated

02/11/25

Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,000 at MacquarieMacquarie analyst Tony Ren lowered the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,000.00 (from JPY2,200.00) while maintaining a Outperform rating.

Motoya KohtaniNomura

Nomura

$15.58→$14.22

Buy

42.21%

Upside

Reiterated

10/31/24

Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,100 at Nomura/InstinetNomura/Instinet analyst Motoya Kohtani lowered the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,100.00 (from JPY2,300.00) while maintaining a Buy rating.

Kasumi HarutaUBS

UBS

$12.87

Hold

28.67%

Upside

Reiterated

09/28/24

UBS Reiterates Neutral Rating on Astellas Pharma Inc (4503:JP) (ALPMY)UBS analyst Kasumi Haruta reiterated a Neutral rating and JPY1,900.00 price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Shinichiro MuraokaMorgan Stanley

Morgan Stanley

$10.16

Hold

1.58%

Upside

Reiterated

05/30/25

Morgan Stanley Sticks to Its Hold Rating for Astellas Pharma (ALPMF)

Miki SogiBernstein

Bernstein

$12.87→$10.84

Buy

8.35%

Upside

Reiterated

05/08/25

Analysts Offer Insights on Healthcare Companies: aTyr Pharma (NASDAQ: ATYR), Vir Biotechnology (NASDAQ: VIR) and Astellas Pharma (Other OTC: ALPMF)

Hidemaru YamaguchiCiti

Citi

$16.25→$14.9

Buy

48.98%

Upside

Reiterated

05/01/25

Stephen BarkerJefferies

Jefferies

$10.16

Hold

1.58%

Upside

Reiterated

04/24/25

Analysts Offer Insights on Healthcare Companies: Astellas Pharma (Other OTC: ALPMF), Penumbra (NYSE: PEN) and Genmab (NASDAQ: GMAB)

Seiji WakaoJ.P. Morgan

J.P. Morgan

$11.65→$11.51

Hold

15.12%

Upside

Reiterated

03/05/25

J.P. Morgan Remains a Hold on Astellas Pharma (ALPMF)

Tony RenMacquarie

Macquarie

$14.9→$13.54

Buy

35.44%

Upside

Reiterated

02/11/25

Motoya KohtaniNomura

Nomura

$15.58→$14.22

Buy

42.21%

Upside

Reiterated

10/31/24

Kasumi HarutaUBS

UBS

$12.87

Hold

28.67%

Upside

Reiterated

09/28/24

UBS Reiterates Neutral Rating on Astellas Pharma Inc (4503:JP) (ALPMY)UBS analyst Kasumi Haruta reiterated a Neutral rating and JPY1,900.00 price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Astellas Pharma

1 Month

xxx

Success Rate

3/6 ratings generated profit

Average Return

+0.15%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +0.15% per trade.

3 Months

xxx

Success Rate

1/6 ratings generated profit

Average Return

-4.03%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 16.67% of your transactions generating a profit, with an average return of -4.03% per trade.

1 Year

Miki SogiBernstein

Success Rate

3/6 ratings generated profit

Average Return

+1.38%

reiterated a buy rating 3 months ago

Copying Miki Sogi's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +1.38% per trade.

2 Years

xxx

Success Rate

3/6 ratings generated profit

Average Return

+1.38%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +1.38% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALPMF Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ALPMF has received 6 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ALPMF average Analyst price target in the past 3 months is 11.96.

Each month's total comprises the sum of three months' worth of ratings.

ALPMF Financial Forecast

ALPMF Earnings Forecast

Next quarter’s earnings estimate for ALPMF is $0.13 with a range of $0.07 to $0.20. The previous quarter’s EPS was $0.28. ALPMF beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.93% of the time in the same period. In the last calendar year ALPMF has Outperformed its overall industry.

ALPMF Sales Forecast

Next quarter’s sales forecast for ALPMF is $3.08B with a range of $2.54B to $3.30B. The previous quarter’s sales results were $3.11B. ALPMF beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.39% of the time in the same period. In the last calendar year ALPMF has Outperformed its overall industry.

ALPMF Stock Forecast FAQ

What is ALPMF’s average 12-month price target, according to analysts?

Based on analyst ratings, Astellas Pharma’s 12-month average price target is 11.96.

What is ALPMF’s upside potential, based on the analysts’ average price target?

Astellas Pharma has 19.60% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ALPMF a Buy, Sell or Hold?

Astellas Pharma has a consensus rating of Moderate Buy which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.

What is Astellas Pharma’s price target?

The average price target for Astellas Pharma is 11.96. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $14.90 ,the lowest forecast is $10.16. The average price target represents 19.60% Increase from the current price of $10.

What do analysts say about Astellas Pharma?

Astellas Pharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of ALPMF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Astellas Pharma (ALPMF) Stock Forecast & Price Target

ALPMF Analyst Ratings

ALPMF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Astellas Pharma

ALPMF Analyst Recommendation Trends

ALPMF Financial Forecast

ALPMF Earnings Forecast

ALPMF Sales Forecast

ALPMF Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts